Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
69 hedge funds and large institutions have $13.7M invested in Clearside Biomedical in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 33 closing their positions.
2,600% more call options, than puts
Call options by funds: $81K | Put options by funds: $3K
1.2% less ownership
Funds ownership: 3.86% → 2.66% (-1.2%)
22% less funds holding
Funds holding: 89 → 69 (-20)
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
61% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 33
88% less capital invested
Capital invested by funds: $114M → $13.7M (-$100M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.85M |
| 2 |
Renaissance Technologies
New York
|
+$1.47M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.37M |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$730K |
| 5 |
FI
Fosun International
Hong Kong,
China
|
+$515K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.71M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$6M |
| 3 |
AIC
AWM Investment Company
New York
|
-$5.38M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$3.73M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$3.58M |
CLSD Hedge Fund Activity: Q4 2018 in Review
69 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2018, worth a combined $13.7M — down 88% from $114M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of CLSD and 13 opened new positions — a net loss of 20 holders — while 26 trimmed existing stakes and 19 added.
The largest buyer was UBS Group, adding an estimated $2.85M. The largest seller was Wellington Management Group, cutting an estimated $6.71M.
- 69 institutional investors held Clearside Biomedical (CLSD) as of Q4 2018, down from 89 in Q3 2018.
- Funds reported $13.7M of Clearside Biomedical stock for Q4 2018, down 88% quarter-over-quarter.
- 13 funds opened new Clearside Biomedical positions in Q4 2018 and 33 closed out, a net change of -20 holders.
- The largest Clearside Biomedical buyer in Q4 2018 was UBS Group, an estimated $2.85M added.
- The largest Clearside Biomedical seller in Q4 2018 was Wellington Management Group, an estimated $6.71M sold.
Based on aggregated 13F filings for Q4 2018.